Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Center to Use 454 Sequencing, NimbleGen Arrays in Disease Studies

NEW YORK (GenomeWeb News) – The Oxford Biomedical Research Centre will install several 454 GS FLX sequencing instruments and will use NimbleGen arrays to conduct genome-wide studies focused on finding links between human diseases and genetic mutations, 454 and NimbleGen parent company Roche said Thursday.
OxBRC is a partnership between Oxford Radcliffe Hospitals NHS Trust and the University of Oxford.
Oxford will use the NimbleGen arrays as a preparative tool for sequencing and genome-wide studies of samples with clinical documentation for selected diseases in three areas.
The researchers will sequence several genes for private familial mutations, they will conduct mutation screening in a large number of genes using both the 454 and NimbleGen technologies, and they will seek to identify genes and regions with genomic imbalances using the NimbleGen CGH Arrays.
Financial terms of the agreement were not released.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.